Alzheimer's and prion disease as disorders of protein conformation: Implications for the design of novel therapeutic approaches

Journal of Molecular Medicine

Volumn 77, Issue 5, 1999, Pages 412-418

  Soto, Claudio ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Sheet breaker peptides; Alzheimer's disease; Protein conformation; Spongiform encephalopathies; Therapy

Indexed keywords

AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; PRION PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFORMATIONAL TRANSITION; DRUG DESIGN; GENE MUTATION; MOUSE; NONHUMAN; PRION DISEASE; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN SECONDARY STRUCTURE; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN CHEMISTRY; HUMANS; MUTATION; PEPTIDES; PRION DISEASES; PRIONS; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY;

EID: 0033044804     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050371     Document Type: Review

References (74)

1. 1. Tobias DJ, Sneddon SF, Brooks CL (1992) Stability of a model β-sheet in water. J Mol Biol 227:1244-1252
2. 2. Wetzel R (1996) For protein misassembly, it's the "I" decade. Cell 86:699-702
3. 3. Thomas PJ, Qu B-H, Pedersen PL (1995) Defective protein folding as a basis of human disease. Trends Biochem Sci 20:456-459
4. 4. Sifers RN (1995) Defective protein folding as a cause of disease. Nat Struct Biol 2:355-357
5. 5. Kelly JW (1996) Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol 6:11-17
6. 6. Carrell RW, Lomas DA (1997) Conformational disease. Lancet 350:134-138
7. 7. Katzman R, Saitoh T (1991) Advances in Alzheimer's disease. FASEB J 5:278-286
8. 8. Kang J, Lemaire HG, Unterbeck A, et al (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733-736
9. 9. Robakis NK, Ramakrishna N, Wolfe G, Wisniewski HM (1987) Molecular cloning and characterization of a cDNA encoding the neuritic plaque amyloid peptides. Proc Natl Acad Sci USA 84:4190-4194
10. 10. Goldgaber D, Lerman MI, McBride OW, Saffiotti U, Gajdusek DC (1987) Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 235:877-880
11. 11. Tanzi RE, Gusella JF, Watkins PC, et al (1987) Amyloid β-protein gene: cDNA, mRNA distribution and genetic linkage near the Alzheimer's locus Science 235:880-884
12. 12. Wisniewski KE, Wisniewski HM, Wen GY (1985) Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 17:278-282
13. 13. Mann DM, Jones D, Prinja D, Purkiss MS (1990) The prevalence of amyloid (A4) protein deposits within the cerebral and cerebellar cortex in Down's syndrome and Alzheimer's disease. Acta Neuropathol (Berl) 80:318-327
14. 14. Chartier-Harlin M-C, Crawford F, Houlden H, et al (1991) Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature 353:844-846
15. 15. Mullan M, Crawford F, Axelman K, et al (1992) A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N terminus of amyloid. Nat Genet 1:345-347
16. 16. Corder EH, Saunders AM, Strittmatter WJ, et al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923
17. 17. Strittmatter WJ, Saunders AM, Schmechel D, et al (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90:1977-1981
18. 18. Sherrington R, Rogaev EI, Liang Y, et al (1995) Cloning of a gene bearing missense mutations in early onset familial Alzheimer's disease. Nature 375:754-760
19. 19. Levy-Lahad E, Wasco W, Poorkaj P, et al (1995) Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269:973-977
20. 20. Rogaev E, Sherrington R, Rogaeva EA, et al (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376:775-778
21. 21. Citron M, Oltersdorf T, Haass C, et al (1992) Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360:672-674
22. 22. Suzuki N, Cheung TT, Cai TT, et al (1994) An increase percentage of long amyloid β protein secreted by familial amyloid β protein precursor (β PP717) mutants. Science 264: 1336-1340
23. 23. Ma J, Yee A, Brewer HB, Das S, Potter H (1994) Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372:92-94
24. 24. Wisniewski T, Castaño EM, Golabek A, Vogel T, Frangione B (1994) Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 145:1030-1035
25. 25. Castaño EM, Prelli F, Wisniewski T, et al (1995) Fibrillogenesis in Alzheimer's disease of amyloid-β peptide and apolipoprotein E. Biochem J 305:599-604
26. 26. Citron M, Westaway D, Xia WM, et al (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat Med 3:67-72
27. 27. Borchelt DR, Thinakaran G, Eckman CB, et al (1996) Familial Alzheimer's dis ease-linked presenilin 1 variants elevate Aβ 1-42/1-40 ratio in vitro and in vivo. Neuron 17:1005-1013
28. 28. Lemere CA, Lopera F, Kosik KS, et al (1996) The E280 a presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology. Nat Med 2:1146-1150
29. 29. Mann DMA, Iwatsubo T, Nochlin D, et al (1997) Amyloid deposition in chromosome 1-linked Alzheimer's disease: the Volga German families. Ann Neurol 41:52-57
30. 30. Games D, Adams D, Alessandrini R, et al (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373:523-527
31. 31. Hsiao KK, Chapman P, Nilsen S, et al (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274:99-102
32. 32. Calhoun ME, Wiederhold KH, Abramowski D, et al (1998) Neuron loss in APP transgenic mice. Nature 395:755-756
33. 33. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW (1993) Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13: 1676-1687
34. 34. Lorenzo A, Yankner BA (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 91:12243-12247
35. 35. Selkoe DJ (1994) Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Ann Rev Cell Biol 10:373-403
36. 36. Muller-Hill B, Beyreuther K (1989) Molecular biology of Alzheimer's disease. Annu Rev Biochem 58:287-307
37. 37. Haass C, Schlossmacher MG, Hung AY, et al (1992) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359:322-325
38. 38. Seubert P, Vigo-Pelfrey C, Esch F, et al (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359:325-327
39. 39. Shoji M, Golde TE, Ghiso J, et al (1992) Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258:126-129
40. 40. Soto C, Branes MC, Alvarez J, Inestrosa NC (1994) Structural determinants of the Alzheimer's amyloid beta-peptide. J Neurochem 63:1191-1198
41. 41. Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K (1992) Substitutions of hydrophobic amino acids reduce the amyloidogenieity of Alzheimer's disease βA4 peptides. J Mol Biol 228:460-473
42. 42. Jarrett JT, Berger EP, Lansbury PT Jr (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 31:12345-12352
43. 43. Barrow CJ, Zagorski MG (1991) Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. Science 253:179-182
44. 44. Burdick D, Soreghan B, Kwon M, et al (1992) Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem 267:546-554
45. 45. Zagorski MG, Barrow CJ (1992) NMR studies of amyloid beta-peptides: proton assignments, secondary structure, and mechanism of an alpha-helix-beta-sheet conversion for a homologous, 28-residue, N-terminal fragment. Biochemistry 31:5621-5631
46. 46. Soto C, Castaño EM, Frangione B, Inestrosa NC (1995) The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J Biol Chem 270:3063-3067
47. 47. Soto C, Frangione B (1995) Two conformational states of amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease. Neurosci Lett 186:115-118
48. 48. Soto C, Castaño EM (1996) The conformation of Alzheimer's ß peptide determines the rate of amyloid formation and its resistance to proteolysis. Biochem J 314:701-707
49. 49. Soto C, Ghiso J, Frangione B (1997) Alzheimer's amyloid-β aggregation is modulated by the interaction of multiple factors. Alzheimers Res 3:215-222
50. 50. Schmechel DE, Saunders AM, Strittmatter WJ, et al (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:9649-9653
51. 51. Golabek AA, Soto C, Vogel T, Wisniewski T (1996) The interaction between Alzheimer β-peptide and apolipoprotein E is dependent on β-peptide conformation. J Biol Chem 271: 10602-10606
52. 52. Soto C, Golabek AA, Wisniewski T, Castaño EM (1996) Alzheimer's soluble β-amyloid is conformationally modified by apolipoproteins in vitro. Neuroreport 7:721-725
53. 53. Wisniewski T, Frangione B (1992) Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 135:235-238
54. 54. Bales KR, Verina T, Dodel RC, et al (1997) Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Gen 17:254-256
55. 55. Prusiner SB, Scott M, DeArmond SJ, Cohen FE (1998) Prion protein biology. Cell 93:337-348
56. 56. Prusiner SB (1991) Molecular biology of prion diseases. Science 252:1515-1522
57. 57. Roos R, Gajdusek DC, Gibbs CJ Jr (1973) The clinical characteristics of trnsmissible Creutzfeldt-Jakob disease. Brain 96:1-20
58. 58. Bueler H, Aguzzi A, Sailer A, et al (1993) Mice devoid of PrP are resistant to scrapie. Cell 73:1339-1347
59. 59. Stahl N, Baldwin MA, Teplow DB, et al (1993) Structural studies of the scrapie prion protein using mass spectrometry and amino acid sequencing. Biochemistry 32:1991-2002
60. 60. Pan KM, Baldwin M, Njuyen J, et al (1993) Conversion of alpha-helices into β-sheets features in the formation of scrapie prion poteins. Proc Natl Acad Sci USA 90:10962-10966
61. 61. Baldwin MA, Cohen FE, Prusiner SB (1995) Prion protein isoforms, a convergence of biological and structural investigations. J Biol Chem 270:19197-19200
62. 62. Cohen F E, Pan K M, Huang Z, et al (1994) Structural clues to prion replication. Science 264:530-531
63. 63. Telling GC, Scott M, Mastrianni J, et al (1995) Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 83:79-90
64. 64. Kascsak RJ, Rubenstein R, Carp RI (1991) Evidence for biological and structural diversity among scrapie strains. Curr Top Microbiol Immunol 172:139-150
65. 65. Kocisko DA, Come JH, Priola SA, et al (1994) Cell-free formation of pro tease-resistant prion protein. Nature 370:471-474
66. 66. Harrison PM, Bamborough P, Daggett V, Prusiner SB, Cohen FE (1997) The prion folding problem. Curr Opin Struct Biol 7:53-59
67. 67. Prusiner SB (1998) Prions. Proc Natl Acad Sci USA 95: 13363-13383
68. 68. Bessen RA, Marsh RF (1994) Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J Virol 68:7859-7868
69. 69. Telling GC, Parchi P, DeArmond SJ, Cortelli P, et al (1996) Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 274:2079-2082
70. sc molecules with different conformations. Nat Med 4:1157-1165
71. 71. Caughey B, Raymond GJ, Bessen RA (1998) Strain-dependent differences in β-sheet conformation of abnormal prion protein. J Biol Chem 273:32230-32235
72. 72. Soto C, Kindy MS, Baumann M, Frangione B (1996) Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation. Biochem Biophys Res Commun 226: 672-680
73. 73. Soto C, Sigurdsson EM, Morelli L, et al (1998) β-sheet breaker peptides prevent Alzheimer's amyloid-β neurotoxicity in cell culture and inhibit fibrillogenesis in vitro and in a rat brain model of amyloidosis. Nat Med 4:822-826
74. 74. Abagyan RA, Totrov MM, Kuznetsov DA (1994) ICM: a new method for structure modeling and design: application to docking and structure prediction from the distorted native conformation. J Comp Chem 15:488-506